Health Care & Life Sciences » Biotechnology | Xenetic Biosciences Inc.

Xenetic Biosciences Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
4,905.50
2,573.40
198.70
4,114.60
5,599.60
638.10
Total Accounts Receivable
256.00
115.80
-
3,000.00
-
-
Other Current Assets
168.30
88.20
3,991.80
1,224.00
285.00
555.90
Total Current Assets
5,329.80
2,777.40
4,190.60
8,338.70
5,884.60
1,194
Net Property, Plant & Equipment
152.60
119.40
62.00
42.40
27.80
5
Intangible Assets
13,983.20
13,220.00
12,526.50
12,526.50
12,526.50
12,526.50
Other Assets
-
199.30
129.30
66.30
724.70
705.70
Total Assets
19,465.60
16,316.10
16,908.40
20,973.90
19,163.60
14,431.10
ST Debt & Current Portion LT Debt
681.10
-
4,047.70
-
-
Accounts Payable
942.20
-
-
1,006.90
786.80
Other Current Liabilities
1,966.70
2,698.90
3,294.70
859.10
1,156.90
Total Current Liabilities
3,590.00
2,698.90
7,342.40
1,866.00
1,943.70
Long-Term Debt
-
56.40
-
-
-
Deferred Taxes
3,257.90
3,080.10
2,918.50
2,918.50
2,918.50
Other Liabilities
-
-
38.80
19.90
-
Total Liabilities
6,847.90
5,835.40
10,299.70
4,804.40
4,862.20
Common Equity (Total)
12,617.70
10,480.70
6,608.70
16,166.20
14,298.40
Total Shareholders' Equity
12,617.70
10,480.70
6,608.70
16,169.50
14,301.50
Total Equity
12,617.70
10,480.70
6,608.70
16,169.50
14,301.50
Liabilities & Shareholders' Equity
19,465.60
16,316.10
16,908.40
20,973.90
19,163.60
Preferred Stock (Carrying Value)
-
-
-
3.30
3.10

About Xenetic Biosciences

View Profile
Address
40 Speen Street
Framingham Massachusetts 01701
United States
Employees -
Website http://www.xeneticbio.com
Updated 07/08/2019
Xenetic Biosciences, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, research, and development of next generation biologic drugs and novel orphan oncology therapeutics. Its lead investigational product candidate is oncology therapeutic XBIO-101 (sodium cridanimod), which focuses on the treatment of progesterone resistant endometrial cancer. It also offers proprietary drug development platform, PolyXen, which enables next-generation biologic drugs by improving their half-life and other pharmacological properties.